Can a dengue vaccine be both Cost-Effective and trusted? a thai study investigates
NCT ID NCT07759596
First seen Aug 12, 2026 · Last updated Aug 13, 2026 · Updated 1 time
Summary
This study has two parts. First, researchers will use computer models to estimate whether giving the TAK-003 dengue vaccine to Thai children aged 9-14 or young adults aged 15-24 would be good value for money for the national immunization program. Second, they will survey Thai adults and parents of children aged 4-18 to understand what influences their willingness to get the dengue vaccine, including beliefs, concerns, and cost. The goal is to provide evidence that could help Thailand decide how to roll out dengue vaccination effectively and build public trust.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- TAK-003 dengue vaccine (evaluated for cost-effectiveness, not administered to participants)
- What this could lead to
- If successful, this could guide Thailand's decision on adding the dengue vaccine to its national immunization program, potentially reducing dengue burden in high-risk age groups.
- What could go wrong
- This is an economic and survey-based study, not a clinical efficacy trial. Results depend on model assumptions and survey responses, which may not reflect real-world vaccine uptake or long-term effectiveness.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for DENGUE FEVER are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Locations
-
Hospital for Tropical Diseases, Faculty of Tropical Medicine
Bangkok, Thailand
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Dengue vaccine booster put to the test: can it shield against all four virus types?
- Flu drug zanamivir tested against Dengue's deadliest complication
- AI toolkit aims to speed up epidemic response for diseases like COVID-19 and mpox
- Could a new vaccine shield infants from dengue?
- Ultrasound clues could predict dangerous dengue
- Malaysia monitors QDENGA vaccine safety in 2,000 people